Epithelial ovarian cancer: Role of pegylated liposomal doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 361-366

  Tanguay, J S ^a,b   Ansari, J ^a   Buckley, L ^a   Fernando, I ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Ca125; Epithelial ovarian cancer; Pegylated liposomal doxorubicin; Platinum free interval

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETREATMENT; SURVIVAL TIME; TREATMENT RESPONSE;

CA-125 ANTIGEN; CARCINOMA, PAPILLARY; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; POLYETHYLENE GLYCOLS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68149161635     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a1c7aa     Document Type: Article

References (18)

1. Kavanagh H., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 1995;13:1584-588.
2. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4:87-4. Review.
3. Coleman RL. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist. 2007;12:72-78.
4. Sabbatini P., Mooney D., Iasonos A., et al. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. Int J Gynecol Cancer. 2007;17:589-594.
5. National Institute for Health and Clinical Excellence Guidance. TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review): Guidance, 25 May 2005. (http://www.nice.org.uk/TA091).
6. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21:187s-193s. Review.
7. Gossner G. Ca125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006;103:212-218.
8. Gronlund B., Hansen HH, HLgdall C., et al. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer. 2004;90:377-382.
9. Leticia BA, Rangel, et al. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene. 2003;22:7225-7232.
10. Gordon AN, Tonda M., Sun S., et al. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8.
11. Deleted in proof.
12. Deleted in proof.
13. Simon I., et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006;66:1570-1575. February 1, 2006.
14. Luo L-Y, et al. Human kallikrein 10: a novel tumor marker for ovarian carcinoma. Clin Chim Acta. 2001;306:111-118 (26 ref.).
15. Brown A. Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer. J Clin Oncol. 2008;26:5533 (May 20 suppl; abstr).
16. Blackledge G., Lawton F., Redman C., et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59:650-653.
17. Markman M., Markman J., Webster K., et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120-3125.
18. Pignata S. Extending the platinum free interval with a non platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the Socrates Retrospective Study. Oncology. 2006;71:309-311.